Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam
2007; Wiley; Volume: 47; Issue: 6 Linguagem: Inglês
10.1177/0091270007300807
ISSN1552-4604
AutoresAnup Majumdar, Kerri X. Yan, Diana Selverian, Suna Barlas, M.L. Constanzer, James Dru, Jacqueline B. McCrea, Tuli Ahmed, Glen Frick, Walter K. Kraft, Kevin J. Petty, Howard Greenberg,
Tópico(s)Anesthesia and Pain Management
ResumoOral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg +/- oral aprepitant 125 mg. The hypothesis was that midazolam AUC would not change by more than 2-fold (consistent with no more than weak inhibition) when midazolam + aprepitant was compared with midazolam alone. An AUC geometric mean ratio (midazolam + aprepitant/midazolam) with 90% confidence interval upper bound < or =2.0 (an increase in midazolam felt to be of modest clinical significance in the highly monitored perioperative period) was prespecified. Aprepitant increased intravenous midazolam AUC(0-infinity) 1.47-fold (90% confidence interval, 1.36-1.59), which fell within the prespecified criterion.
Referência(s)